Introducing a new entity: chemotherapy-induced arrhythmia
Open Access
- 3 October 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (12), 1579-1586
- https://doi.org/10.1093/europace/eup300
Abstract
The relationship between chemotherapy and arrhythmias has not been well established. We reviewed the existing literature to better understand this connection. We reviewed published reports on chemotherapy-induced arrhythmias in English using the PubMed/Medline and OVID databases from 1950 onwards as well as lateral references. Arrhythmias were reported as a side effect of many chemotherapeutic drugs. Anthracyclines are associated with atrial fibrillation (AF) at a rate of 2–10%, but rarely with ventricular tachycardia (VT)/fibrillation. Taxol and other antimicrotubular drugs are safe in terms of pro-arrhythmic side effects and do not cause any consistent rhythm abnormalities. Arrhythmias induced by 5-fluorouracil, including VT, are mostly ischaemic in origin and usually occur in the context of coronary spasm produced by this drug. Cisplatin—particularly with intrapericardial use—is associated with a very high rate of AF (12–32%). Melphalan is associated with AF in 7–12% of cases, but it does not appear to cause VT. Interleukin-2 is linked to frequent arrhythmia, mostly AF. We summarized the available data on chemotherapy-induced arrhythmia, particularly AF and VT. Studies with prospective data collection and thorough analyses are needed to establish a causal relationship between certain anticancer drugs and arrhythmia.Keywords
This publication has 92 references indexed in Scilit:
- 5-Fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoringInternational Journal of Clinical Practice, 2007
- Two Cases of Acute Promyelocytic Leukemia Complicated by Torsade de Pointes during Arsenic Trioxide TherapyInternational Journal of Hematology, 2006
- The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)European Journal of Cancer, 2005
- The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative TrialClinical Cancer Research, 2005
- Effect of Arsenic Trioxide on QT Interval in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Ventricular repolarization time indexes following anthracycline treatmentHeart and Vessels, 1997
- Clinical Cardiotoxicity of 5‐FluorouracilThe Journal of Clinical Pharmacology, 1993
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneThe New England Journal of Medicine, 1987
- Arsenic-Induced Atypical Ventricular TachycardiaThe New England Journal of Medicine, 1980